About this trial

Pramlintide is a peptide analogue of human amylin which is a vasoactive substance involved in the pathogenesis of headache. This study investigates whether pramlintide induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).

Eligibility criteria

Qualifiers

Age 18 to 65 years of age upon entry into screening

History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)

≥ 4 monthly headache days on average across the 3 months prior to screening

Provision of informed consent prior to initiation of any study-specific activities/procedures

Disqualifiers

> 1 mild traumatic injury to the head

History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)

History of moderate or severe injury to the head

History of whiplash injury

Trial design

Treatments tested in this trial

  • Amylin
  • Placebo

Treatment groups

21 Participants
are divided into 2 treatment groups

Locations

1
Rigshospitalet Glostrup2600, Glostrup Municipality Denmark

Sponsors and collaborators

Danish Headache Center

Lead sponsor